Accelerated Pharma (Accelerated Pharma) EV-to-Revenue : (As of May. 17, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Accelerated Pharma EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Accelerated Pharma's enterprise value is $0.00 Mil. Accelerated Pharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2017 was $0.00 Mil. Therefore, Accelerated Pharma's EV-to-Revenue for today is .

The historical rank and industry rank for Accelerated Pharma's EV-to-Revenue or its related term are showing as below:

ACCP's EV-to-Revenue is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 2.415
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-17), Accelerated Pharma's stock price is $0.00. Accelerated Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2017 was $0.00. Therefore, Accelerated Pharma's PS Ratio for today is .

Accelerated Pharma EV-to-Revenue Historical Data

The historical data trend for Accelerated Pharma's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerated Pharma EV-to-Revenue Chart

Accelerated Pharma Annual Data

Trend

Dec14

Dec15

Dec16

EV-to-Revenue

Accelerated Pharma Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
EV-to-Revenue	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Accelerated Pharma's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Accelerated Pharma's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Accelerated Pharma's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Accelerated Pharma's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Accelerated Pharma's EV-to-Revenue falls into.

Accelerated Pharma EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Accelerated Pharma's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	0.000	/	0
	=

Accelerated Pharma's current Enterprise Value is $0.00 Mil.
Accelerated Pharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Accelerated Pharma (NAS:ACCP) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Accelerated Pharma's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	0.00	/	0
	=

Accelerated Pharma's share price for today is $0.00.
Accelerated Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

Accelerated Pharma EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Accelerated Pharma's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Accelerated Pharma (Accelerated Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Accelerated Pharma Inc (NAS:ACCP) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Accelerated Pharma Inc, is a Delaware corporation organized on May 12, 2014. It is a biopharmaceutical company focused on utilizing its genomic technology to enhance the development and commercialization of pharmaceutical products. Its lead product candidate is Picoplatin, a new generation platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications.

Accelerated Pharma (Accelerated Pharma) Headlines

No Headlines